pirfenidone has been researched along with Invasiveness, Neoplasm in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, L; Deng, P; Hu, C; Li, Y; Liu, J; Pan, P; Yang, H | 1 |
| Aboulkheyr Es, H; Thiery, JP; Warkiani, ME; Zhand, S | 1 |
| Cardone, RA; Carvalho, TMA; Koltai, T; Reshkin, SJ | 1 |
3 other study(ies) available for pirfenidone and Invasiveness, Neoplasm
| Article | Year |
|---|---|
Pirfenidone promotes the levels of exosomal miR-200 to down-regulate ZEB1 and represses the epithelial-mesenchymal transition of non-small cell lung cancer cells.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MicroRNAs; Neoplasm Invasiveness; Pyridones; Tumor Microenvironment; Zinc Finger E-box-Binding Homeobox 1 | 2022 |
Pirfenidone reduces immune-suppressive capacity of cancer-associated fibroblasts through targeting CCL17 and TNF-beta.
Topics: Antineoplastic Agents; B7-H1 Antigen; Breast Neoplasms; Cancer-Associated Fibroblasts; Cell Line, Tumor; Cells, Cultured; Chemokine CCL17; Gene Expression Regulation, Neoplastic; Humans; Immunosuppression Therapy; Lymphotoxin-alpha; Neoplasm Invasiveness; Pyridones; Tumor Microenvironment | 2020 |
Targeting the Stromal Pro-Tumoral Hyaluronan-CD44 Pathway in Pancreatic Cancer.
Topics: Adenocarcinoma; Bromelains; Carcinoma, Pancreatic Ductal; Cell Movement; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Hyaluronan Receptors; Hyaluronan Synthases; Hyaluronic Acid; Hymecromone; Molecular Targeted Therapy; Neoplasm Invasiveness; Neoplasm Metastasis; Pyridones; Signal Transduction | 2021 |